Organovo Holdings Company Profile (NASDAQ:ONVO)

About Organovo Holdings (NASDAQ:ONVO)

Organovo Holdings logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONVO
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $2.68
  • 200 Day Moving Avg: $3.01
  • 52 Week Range: $2.30 - $4.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.97
  • P/E Growth: 0.00
  • Net Margins: -908.91%
  • Return on Equity: -63.92%
  • Return on Assets: -58.77%
  • Current Ratio: 10.83%
  • Quick Ratio: 10.74%
  • Average Volume: 824,894 shs.
  • Beta: 2.99
Frequently Asked Questions for Organovo Holdings (NASDAQ:ONVO)

What is Organovo Holdings' stock symbol?

Organovo Holdings trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo Holdings' earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Wednesday, June, 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.76 million. Organovo Holdings had a negative net margin of 908.91% and a negative return on equity of 63.92%. The firm's revenue was up 700.0% on a year-over-year basis. View Organovo Holdings' Earnings History.

Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?

4 analysts have issued 1 year price objectives for Organovo Holdings' stock. Their forecasts range from $3.75 to $15.00. On average, they anticipate Organovo Holdings' share price to reach $6.94 in the next year. View Analyst Ratings for Organovo Holdings.

Who are some of Organovo Holdings' key competitors?

Who are Organovo Holdings' key executives?

Organovo Holdings' management team includes the folowing people:

  • Keith E. Murphy, Chairman of the Board
  • Taylor J. Crouch, President, Chief Executive Officer
  • Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer
  • Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
  • Paul Gallant, General Manager
  • Robert F. Baltera Jr., Lead Independent Director
  • James T. Glover, Independent Director
  • Richard A. Heyman Ph.D., Independent Director
  • Tamar D. Howson, Independent Director

Who owns Organovo Holdings stock?

Organovo Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Quotient Investors LLC (0.00%). Company insiders that own Organovo Holdings stock include Eric David and Keith Murphy. View Institutional Ownership Trends for Organovo Holdings.

How do I buy Organovo Holdings stock?

Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo Holdings' stock price today?

One share of Organovo Holdings stock can currently be purchased for approximately $2.37.

MarketBeat Community Rating for Organovo Holdings (NASDAQ ONVO)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Organovo Holdings (NASDAQ:ONVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.94 (192.72% upside)

Analysts' Ratings History for Organovo Holdings (NASDAQ:ONVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017Evercore ISIReiterated RatingOutperform$4.00 -> $3.75LowView Rating Details
6/8/2017Jefferies Group LLCReiterated RatingBuy$4.50 -> $4.00MediumView Rating Details
1/25/2017Raymond James Financial, Inc.Initiated CoverageOutperform$5.00N/AView Rating Details
12/15/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for Organovo Holdings (NASDAQ:ONVO)
Earnings by Quarter for Organovo Holdings (NASDAQ:ONVO)
Earnings History by Quarter for Organovo Holdings (NASDAQ ONVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/7/2017Q4 2017($0.11)($0.10)$0.76 million$0.80 millionViewListenView Earnings Details
2/9/2017Q3 2017($0.10)($0.09)$1.40 million$1.15 millionViewListenView Earnings Details
11/3/2016Q217($0.11)($0.10)$0.50 million$1.38 millionViewListenView Earnings Details
8/4/2016Q1($0.10)($0.09)$0.30 million$0.89 millionViewListenView Earnings Details
6/9/2016Q4($0.11)($0.09)$0.10 million$0.55 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Organovo Holdings (NASDAQ:ONVO)
2019 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20191($0.08)($0.08)($0.08)
Q2 20191($0.08)($0.08)($0.08)
Q3 20191($0.08)($0.08)($0.08)
Q4 20191($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)


Dividend History for Organovo Holdings (NASDAQ:ONVO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Organovo Holdings (NASDAQ:ONVO)
Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 22.72%
Insider Trades by Quarter for Organovo Holdings (NASDAQ:ONVO)
Institutional Ownership by Quarter for Organovo Holdings (NASDAQ:ONVO)
Insider Trades by Quarter for Organovo Holdings (NASDAQ:ONVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2017Keith MurphyCEOSell25,000$3.68$92,000.00View SEC Filing  
1/24/2017Keith MurphyCEOSell25,000$3.51$87,750.00View SEC Filing  
12/14/2016Keith MurphyCEOSell50,000$3.72$186,000.00View SEC Filing  
8/5/2016Eric DavidEVPSell20,000$4.55$91,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Organovo Holdings (NASDAQ:ONVO)
Latest Headlines for Organovo Holdings (NASDAQ:ONVO)
DateHeadline logo$880,000.00 in Sales Expected for Organovo Holdings, Inc. (NASDAQ:ONVO) This Quarter - July 20 at 11:44 AM logoOrganovo Announces Release Date for Fiscal First-Quarter 2018 Financial Results - July 19 at 12:55 AM logoHow Risky Is Organovo Holdings, Inc.? - July 18 at 4:13 PM logoOrganovo - Going The Right Direction - Seeking Alpha - July 15 at 7:12 AM logoETFs with exposure to Organovo Holdings, Inc. : July 13, 2017 - July 14 at 7:09 AM logoZacks: Brokerages Set $4.50 Target Price for Organovo Holdings, Inc. (NASDAQ:ONVO) - July 12 at 8:34 AM logoHere's Why Organovo Holdings Inc Fell 10.5% in June - July 11 at 6:24 AM logoETFs with exposure to Organovo Holdings, Inc. : July 3, 2017 - July 4 at 2:59 AM logoZacks: Organovo Holdings, Inc. (ONVO) Given $4.50 Average Target Price by Analysts - June 27 at 10:10 AM logo$880,000.00 in Sales Expected for Organovo Holdings, Inc. (ONVO) This Quarter - June 24 at 9:30 AM logoFeatured Company News - Pamplona to Acquire PAREXEL; Another Contract Researcher Goes Private - June 23 at 8:47 AM logoETFs with exposure to Organovo Holdings, Inc. : June 22, 2017 - June 23 at 8:47 AM logo3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More - June 22 at 4:32 PM logo Brokerages Anticipate Organovo Holdings, Inc. (ONVO) Will Announce Earnings of -$0.10 Per Share - June 22 at 12:23 PM logoZacks: Brokerages Set $4.50 Price Target for Organovo Holdings, Inc. (ONVO) - June 15 at 2:52 PM logoETFs with exposure to Organovo Holdings, Inc. : June 12, 2017 - June 12 at 6:44 PM logoAnalysts Offer Predictions for Organovo Holdings, Inc.'s FY2019 Earnings (ONVO) - June 12 at 9:50 AM logoOrganovo Holdings, Inc. :ONVO-US: Earnings Analysis: 2017 By the Numbers : June 9, 2017 - June 9 at 7:15 PM logoOrganovo Holdings' (ONVO) "Outperform" Rating Reiterated at Evercore ISI - June 9 at 6:58 PM logoOrganovo Holdings Inc to Post Q1 2019 Earnings of ($0.08) Per Share, Jefferies Group Forecasts (ONVO) - June 9 at 2:20 PM logoOrganovo Holdings Inc (ONVO) Stock Rating Reaffirmed by Jefferies Group LLC - June 8 at 9:10 PM logoEdited Transcript of ONVO earnings conference call or presentation 7-Jun-17 9:00pm GMT - June 8 at 9:31 AM logoOrganovo Holdings Still Not Back on Track - June 8 at 9:31 AM logoOrganovo Holdings Inc (ONVO) Announces Quarterly Earnings Results - June 8 at 8:14 AM logoOrganovo to Present at Jefferies Healthcare Conference - GlobeNewswire (press release) - June 5 at 7:39 PM logo Analysts Expect Organovo Holdings Inc (ONVO) Will Announce Quarterly Sales of $630,000.00 - May 31 at 2:48 PM logoOrganovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 29, 2017 - May 29 at 8:34 AM logoOrganovo Holdings Inc (ONVO) Expected to Announce Earnings of -$0.11 Per Share - May 29 at 8:22 AM logoAnalysts Anticipate Organovo Holdings Inc (ONVO) to Post ($0.11) Earnings Per Share - May 26 at 2:30 PM logoOrganovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress - May 19 at 11:49 AM logoOrganovo Announces Release Date for Fiscal Fourth-Quarter 2017 Financial Results - May 17 at 8:45 AM logoOrganovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 17, 2017 - May 17 at 8:45 AM logoHere's Why Organovo Holdings Stock Fell 5.2% In April - May 11 at 9:03 AM logoResearch Reports Initiation on Medical Labs Stocks -- Organovo, DexCom, Quest ... - May 9 at 11:17 AM logo$630,000.00 in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter - May 5 at 1:38 PM logo Organovo Holdings Inc (ONVO) Given Consensus Rating of "Strong Buy" by Brokerages - May 4 at 9:16 AM logoOrganovo Holdings (ONVO) Receives Daily Media Impact Rating of 0.15 - May 4 at 12:40 AM logo-$0.11 EPS Expected for Organovo Holdings Inc (ONVO) This Quarter - May 3 at 8:24 PM logoOrganovo Holdings, Inc. – Value Analysis (NASDAQ:ONVO) : May 3, 2017 - May 3 at 8:00 PM logoSomewhat Positive Press Coverage Unlikely to Impact Organovo Holdings (ONVO) Share Price - April 30 at 3:26 PM logoFavorable Press Coverage Likely to Impact Organovo Holdings (ONVO) Stock Price - April 28 at 12:36 AM logoClearside Biomedical, Inc. Announces Completion Of Patient Enrollment In Phase 1/2 Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema - April 20 at 9:07 AM logoOrganovo Holdings (ONVO) Given Daily News Impact Score of -0.29 - April 19 at 11:54 AM logoOrganovo Holdings Inc (ONVO) Stock Rating Upgraded by Zacks Investment Research - April 18 at 7:54 AM logoBrokerages Expect Organovo Holdings Inc (ONVO) to Post ($0.11) EPS - April 17 at 6:37 PM logoOrganovo Holdings (ONVO) Given Daily Media Sentiment Score of 0.44 - April 15 at 10:07 AM logoOrganovo Holdings Inc (ONVO) Upgraded by Zacks Investment Research to Hold - April 14 at 10:06 AM logoOrganovo Holdings CEO Leaves: Should Investors Be Worried? - Motley Fool - April 14 at 8:03 AM logoWhat's Next for Organovo Holdings Inc.? - Motley Fool - April 12 at 7:59 PM logoOrganovo Holdings Inc (ONVO) Short Interest Down 4.3% in March - April 12 at 4:22 PM



Organovo Holdings (ONVO) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff